Sunitinib (2 weeks on/1 week off schedule) in metastatic renal cell cancer patients. Progression free and overall survival
Gyergyay, F., Budai, B., Nagyivanyi, K., Biró, K., Géczi, L.Volume:
27
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw373.47
Date:
October, 2016
File:
PDF, 36 KB
english, 2016